Difference in association of obesity with prostate cancer risk between us african american and non-hispanic white men in the selenium and vitamin e cancer prevention trial (SELECT)
Open accessAbstract
IMPORTANCE: African American men have the highest rates of prostate cancer incidence and mortality in the United States. Understanding underlying reasons for this disparity could identify preventive interventions important to African American men. OBJECTIVE: To determine whether the association of obesity with prostate cancer risk differs between African American and non-Hispanic white men and whether obesity modifies the excess risk associated with African American race. DESIGN, SETTING, AND PARTICIPANTS: Prospective study of 3398 African American and 22,673 non-Hispanic white men who participated in the Selenium and Vitamin E Cancer Prevention Trial (2001-2011) with present analyses completed in 2014. MAIN OUTCOMES AND MEASURES: Total, low-grade (Gleason score <7), and high-grade (Gleason score ≥7) prostate cancer incidence. RESULTS: With a median (interquartile range) follow-up of 5.6 (1.8) years, there were 270, 148, and 88 cases of total, low-, and high-grade prostate cancers among African American men and a corresponding 1453, 898, and 441 cases in non-Hispanic white men, respectively. Although not associated with risk among non-Hispanic white men, BMI was positively associated with an increase in risk among African American men (BMI, <25 vs ≥35: hazard ratio [HR], 1.49 [95% CI, 0.95, 2.34]; P for trend = .03). Consequently, the risk associated with African American race increased from 28% (HR, 1.28 [95% CI, 0.91-1.80]) among men with BMI less than 25 to 103% (HR, 2.03 [95% CI, 1.38-2.98]) among African American men with BMI at least 35 (P for trend = .03). Body mass index was inversely associated with low-grade prostate cancer risk within non-Hispanic white men (BMI, <25 vs ≥35: HR, 0.80 [95% CI, 0.58-1.09]; P for trend = .02) but positively associated with risk within African American men (BMI, <25 vs ≥35: HR, 2.22 [95% CI, 1.17-4.21]; P for trend = .05). Body mass index was positively associated with risk of high-grade prostate cancer in both non-Hispanic white men (BMI, <25 vs ≥35: HR, 1.33 [95% CI, 0.90-1.97]; P for trend = .01) and African American men, although the increase may be larger within African American men, albeit the racial interaction was not statistically significant (BMI, <25 vs ≥35: HR, 1.81 [95% CI, 0.79-4.11]; P for trend = .02). CONCLUSIONS AND RELEVANCE: Obesity is more strongly associated with increased prostate cancer risk among African American than non-Hispanic white men and reducing obesity among African American men could reduce the racial disparity in cancer incidence. Additional research is needed to elucidate the mechanisms underlying the differential effects of obesity in African American and non-Hispanic white men.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some reports suggest potential harm from using resveratrol, selenium, and vitamin D.
“Some reports suggest potential harm with the use of these agents.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1718]
The Methods (Participant and Study Description; page unavailable) say SELECT tested selenium and vitamin E supplementation and that trial supplements were discontinued, but give no reason establishing harm. The passages found when searching for supplement-related harm and for resveratrol and vitamin D do not address potential harm from the three agents named in the claim. (LLM, conf=0.72)
Experimental — accuracy not yet measuredResveratrol, selenium, and vitamin D have mixed effects on glycemic control and other cardiovascular risk factors.
“Other nutritional supplements, specifically resveratrol, selenium, and vitamin D, have mixed effects on glycemic control and other CV risk factors.1705,1717–1724”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1718]
The Methods (Participant and Study Description; page unavailable) say SELECT tested selenium and vitamin E for prostate cancer prevention, while this paper analyzed obesity and prostate cancer incidence. Searches for glycemic control and cardiovascular risk factors found no passage assessing the claimed effects of resveratrol, selenium, or vitamin D. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 107
Research works printed but not linked: 1
- [7]Office of the Surgeon General; Office of Disease Prevention and Health Promotion; Centers for Disease Control and Prevention; National Institutes of Health The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity Rockville, MD US Department of Health and Human Services, Public Health Service, Office of the Surgeon General 2001 sect 1. http://www.ncbi.nlm.nih.gov/books/NBK44210/ Accessed March 13, 2015
- Authors
- Barrington, W. E., Schenk, J. M., Etzioni, R., Arnold, K. B., Neuhouser, M. L., Thompson, I. M., Lucia, M. S., & Kristal, A. R.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Barrington, Wendy E.
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-01
- Volume
- 1
- Issue
- 3
- Pages
- 342
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC4570268
- OpenAlex
- W1974313714
- Cited by
- 107
- References
- 41
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 9 · 2023: 25 · 2022: 11 · 2021: 12 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 10 · 2016: 2 · 2015: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA 37429, UM1CA182883, UG1CA189974, U10CA180834, U10CA037429, R25CA094880)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Keywords
- obesity, prostate cancer risk, African American men, racial disparities, body mass index, Gleason score, low-grade prostate cancer, high-grade prostate cancer, selenium, vitamin E, cancer prevention, SELECT trial, prostate cancer incidence
- MeSH terms
- Aged, Black or African American, Canada, Humans, Male, Middle Aged, Obesity, Prospective Studies, Prostatic Neoplasms, Puerto Rico, Risk Factors, Selenium, Time Factors, United States, Vitamin E, Body Mass Index, Incidence, Chi-Square Distribution, Proportional Hazards Models, Anticarcinogenic Agents, Treatment Outcome, Risk Assessment, White People, Health Status Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review